Medtronic Files PMA Application for FDA Approval of Talent(TM) Abdominal Stent Graft System

Submission Further Confirms Broad Patient Benefits of Endovascular Abdominal Aortic Aneurysm Therapy Provided by Medtronic, the Market Leader in Stent Graft Technologies

MINNEAPOLIS--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ), today announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the Talent™ Abdominal Stent Graft System. The Talent Abdominal Stent Graft is a minimally-invasive device that treats dangerous bulges in the aorta, the body’s largest artery that can rupture without warning.

Full text >>